306 related articles for article (PubMed ID: 26345518)
21. The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity.
Chia PL; Chiang K; Snyder R; Dowling A
J Oncol Pharm Pract; 2018 Jun; 24(4):264-271. PubMed ID: 29284360
[TBL] [Abstract][Full Text] [Related]
22. Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography.
Paiva MG; Petrilli AS; Moisés VA; Macedo CR; Tanaka C; Campos O
Pediatr Blood Cancer; 2005 Dec; 45(7):902-8. PubMed ID: 16035077
[TBL] [Abstract][Full Text] [Related]
23. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
24. Role of NOS3 DNA variants in externalizing behavioral problems observed in childhood leukemia survivors.
Marcoux S; Robaey P; Gahier A; Labuda M; Rousseau J; Sinnett D; Moghrabi A; Laverdière C; Krajinovic M
J Pediatr Hematol Oncol; 2013 May; 35(4):e157-62. PubMed ID: 23612386
[TBL] [Abstract][Full Text] [Related]
25. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
26. Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia.
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Blanco JG; González Font AE; Córdova Hurtado LP; Castañeda VL; Fierro IV; Romero LP; Reyes HA
Pharmacogenet Genomics; 2021 Jul; 31(5):108-115. PubMed ID: 34096893
[TBL] [Abstract][Full Text] [Related]
27. Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.
Lapointe MO; Caru M; Curnier D; Raboisson MJ; Andelfinger G; Krajinovic M; Laverdière C; Sinnett D; Périé D
J Pediatr Hematol Oncol; 2023 Mar; 45(2):70-77. PubMed ID: 36161876
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.
Franca R; Rebora P; Bertorello N; Fagioli F; Conter V; Biondi A; Colombini A; Micalizzi C; Zecca M; Parasole R; Petruzziello F; Basso G; Putti MC; Locatelli F; d'Adamo P; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics J; 2017 Jan; 17(1):4-10. PubMed ID: 26644204
[TBL] [Abstract][Full Text] [Related]
29. Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase.
Sachidanandam K; Gayle AA; Robins HI; Kolesar JM
J Oncol Pharm Pract; 2013 Sep; 19(3):269-72. PubMed ID: 23154571
[TBL] [Abstract][Full Text] [Related]
30. HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.
Vaitiekus D; Muckiene G; Vaitiekiene A; Sereikaite L; Inciuraite R; Insodaite R; Cepuliene D; Kupcinskas J; Ugenskiene R; Jurkevicius R; Juozaityte E
Cardiovasc Toxicol; 2021 Jan; 21(1):59-66. PubMed ID: 32748118
[TBL] [Abstract][Full Text] [Related]
31. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
[TBL] [Abstract][Full Text] [Related]
32. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
33. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
[TBL] [Abstract][Full Text] [Related]
34. Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia.
Shimomura Y; Baba R; Watanabe A; Horikoshi Y; Asami K; Hyakuna N; Iwai A; Matsushita T; Yamaji K; Hori T; Tsurusawa M;
Pediatr Blood Cancer; 2011 Sep; 57(3):461-6. PubMed ID: 21298773
[TBL] [Abstract][Full Text] [Related]
35. Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.
Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG)
Br J Haematol; 2009 May; 145(3):376-88. PubMed ID: 19236609
[TBL] [Abstract][Full Text] [Related]
36. Myocardial 2D Strain During Long-Term (>5 Years) Follow-Up of Childhood Survivors of Acute Lymphoblastic Leukemia Treated With Anthracyclines.
Pourier MS; Mavinkurve-Groothuis AMC; Dull MM; Weijers G; Loonen J; Bellersen L; de Korte CL; Kapusta L
Am J Cardiol; 2020 Jul; 127():163-168. PubMed ID: 32444028
[TBL] [Abstract][Full Text] [Related]
37. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.
Henninger C; Huelsenbeck S; Wenzel P; Brand M; Huelsenbeck J; Schad A; Fritz G
Pharmacol Res; 2015 Jan; 91():47-56. PubMed ID: 25462173
[TBL] [Abstract][Full Text] [Related]
38. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.
Chow EJ; Aggarwal S; Doody DR; Aplenc R; Armenian SH; Baker KS; Bhatia S; Blythe N; Colan SD; Constine LS; Freyer DR; Kopp LM; Laverdière C; Leisenring WM; Sasaki N; Vrooman LM; Asselin BL; Schwartz CL; Lipshultz SE
J Clin Oncol; 2023 Apr; 41(12):2248-2257. PubMed ID: 36669148
[TBL] [Abstract][Full Text] [Related]
39. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H
Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
[TBL] [Abstract][Full Text] [Related]
40. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Choi HS; Park ES; Kang HJ; Shin HY; Noh CI; Yun YS; Ahn HS; Choi JY
J Korean Med Sci; 2010 Sep; 25(9):1336-42. PubMed ID: 20808678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
